Horizon Diagnostics, UK NEQAS announce strategic partnership
CAMBRIDGE, U.K.—Horizon Diagnostics, a division of Horizon Discovery, and the United Kingdom National External Quality Assessment Service (UK NEQAS ICC) have announced a strategic partnership agreement for the development of genetically defined reference standards for novel lung cancer biomarkers. With the new standards, variability can be minimized in FISH- and IHC-based diagnostic testing when it comes to prescription of therapies. Per the agreement, UK NEQAS ICC will receive an exclusive license to distribute reference standards pertaining to certain lung cancer biomarkers in the U.K. and elsewhere in Europe for proficiency testing in its quality assessment program.
"We look forward to seeing our genetically defined reference standards adopted in proficiency schemes and as batch controls, ultimately helping to improve the accuracy of diagnostic testing for patients," said Dr. Paul Morrill, commercial director for Horizon Discovery, in a statement.